Keppra Injection (Levetiracetam)

Adult dose

Levetiracetam treatment may be initiated by intravenous or oral administration. When changing the route of administration from oral to intravenous or vice versa, the dose may be administered immediately without dose titration, and the total daily dose and frequency of administration should remain the same. The injection is administered by the intravenous route only and must be diluted before administration. Dilute the dose in 100mL of a compatible diluent and administer by intravenous infusion over 15 minutes. The film-coated tablets and oral solution are administered orally and may be taken regardless of meals with a sufficient amount of water. The daily dose should be divided into 2 equal doses administered twice daily. Monotherapy Adults and adolescents 16 years of age and older The initial dose is 250mg twice daily, increased after 2 weeks to 500mg twice daily. Depending on the clinical response, the dose may be increased by 500mg per day every 2 weeks, up to a maximum dose of 3000mg per day. Adjunctive therapy 1. Partial-onset seizures Adults (18 years of age and older) and adolescents (16 years of age and older) Initiate treatment at 500mg twice daily; depending on clinical response and tolerability, the dose may be increased or decreased by 1000mg per day every 2 to 4 weeks. The maximum recommended dose is 3000mg per day. 2. Primary generalized tonic-clonic seizures Adults (18 years of age and older) and adolescents (16 years of age and older) Initiate treatment at 500mg twice daily and increase the dose by 1,000mg per day every 2 weeks, up to a maximum of 3000mg per day. 3. Patients with renal impairment In adults, adjust the dose according to creatinine clearance and administer twice daily. 4. Patients with hepatic impairment In patients with severe hepatic impairment and creatinine clearance below 60mL/min, reduce the daily maintenance dose by 50%. 5. Older adults (65 years of age and older) Dose adjustment is recommended in older patients with impaired renal function.

Child dose

The safety and efficacy of the injection have not been established in children under 16 years of age; therefore, its use is not recommended. Tablets are not indicated for children 4 years of age or younger, and the oral solution should be administered to infants 1 month of age or older. Oral formulations are not recommended for infants under 1 month of age. For pediatric patients and adolescents weighing less than 50kg with renal impairment, adjust the twice-daily dose according to body weight and creatinine clearance. In children 16 years of age and older with myoclonic seizures and partial-onset seizures, initiate treatment at 500mg twice daily and increase the dose every 2 weeks, up to a maximum of 3000mg per day.

This medication is used for the treatment of epilepsy and may increase the risk of suicidal thoughts, suicidal behavior, and mental health issues such as depression during use. Therefore, patients and caregivers should report any mood changes or unusual behaviors to a healthcare provider immediately. This medication can cause central nervous system side effects such as drowsiness, fatigue, coordination disorders, and behavioral abnormalities, especially in the first 4 weeks of treatment. Stopping the medication abruptly can increase the risk of seizure frequency, so the dosage should be gradually reduced under a doctor's instructions. Patients with an allergy to this medication or similar components should not take it, and those with suicidal thoughts or depression should be especially cautious. Patients with impaired kidney function may require dosage adjustments, and it is recommended to regularly monitor white blood cell counts through blood tests. This medication may induce changes in behavior, aggression, anxiety, and other psychiatric symptoms, so consultation with a doctor is necessary if such symptoms arise. Care should be taken as seizures may worsen upon initial treatment or with dosage increases. Patients with heart disease or abnormal ECG results should also be cautious when taking this medication. Pregnant women or those planning pregnancy should discuss this medication with their healthcare provider, and breastfeeding mothers should consider the potential transfer of the drug through breast milk, possibly requiring cessation of breastfeeding or the medication. Special caution is required for children and the elderly, especially infants under 1 month and children under 4 years of age, who should be administered appropriate formulations and dosages. Activities requiring attention, such as driving or operating machinery, should be approached with caution during the initial use or dosage adjustments due to possible drowsiness. In cases of overdose, symptoms may include drowsiness, agitation, aggression, and reduced consciousness, requiring immediate medical attention. This medication has minimal interactions with other antiepileptic drugs or oral contraceptives, allowing for co-administration without major issues; however, caution may be needed when combined with specific medications. Regular monitoring for adverse reactions or side effects during use is essential, and prompt consultation with healthcare providers is important if unusual symptoms occur.

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, drowsiness, fatigue, coordination movement disorder, behavioral abnormalities, weakness, ataxia, abnormal gait, psychotic symptoms, aggression, agitation, anger, anxiety, emotional blunting, depersonalization, emotional instability, hostility, irritability, suicide attempts, suicidal ideation, excitability, abnormal behavior, aggressiveness, behavioral disorders, mood changes, mood swings, rejection, delusional behavior, hallucinations, confusion, panic attacks, anger, delirium, obsessive-compulsive disorder, headache, dizziness, tremors, balance disorders, amnesia, inability to perform coordinated movements, attention deficits, memory impairment, hyperactivity, insomnia, emotional instability, personality disorders, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, loss of appetite, weight gain, vertigo, diplopia, blurred vision, myalgia, injuries, nasopharyngitis, infections, cough, rash, eczema, itching, thrombocytopenia, chorea-acanthocytosis, dyskinesia, sensory abnormalities, hypersomnia, gait disorders, worsening of seizures, psychotic disorders, abnormal behavior, hallucinations, confusion, panic attacks, anxiety, anger, delirium, obsessive-compulsive disorder, pancreatitis, liver failure, hepatitis, abnormal liver function tests, weight loss, hyponatremia, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, hair loss, muscle weakness, pancytopenia, agranulocytosis, leukopenia, neutropenia, eosinophilia, angioedema, anaphylaxis, acute kidney injury, encephalopathy, neuroleptic malignant syndrome, prolonged QT interval, rhabdomyolysis, increased CPK in the blood, hypotension, agitation, decreased consciousness, respiratory depression, coma, constipation, palpitations, aphasia, movement disorders, impulsive behaviors, psychomotor retardation, edema, cheilitis, abdominal distension, gastrointestinal disorders, hypersalivation, urticaria, sepsis, musculoskeletal rigidity, neck pain, polyuria, dyspnea

This medication should be stored in a sealed container to prevent air or moisture exposure and kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain drug effectiveness and prevents deterioration.

Appearance

A glass vial injection containing a colorless and transparent solution

Package unit

2.5 milliliters/vial [X 10], 5 milliliters/vial [X 10], 10 milliliters/vial [X 10], 15 milliliters/vial [X 10]